BAY 1238097

Drug Profile

BAY 1238097

Alternative Names: BAY-1238097; BET inhibitor

Latest Information Update: 29 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Class Antineoplastics
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Preclinical Cancer; Haematological malignancies

Most Recent Events

  • 29 Nov 2016 Adverse events and pharmacokinetics data from a phase I trial in Solid tumours and lymphoma presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • 07 Apr 2016 Pharmacodynamics data from preclinical and in vitro studies in Melanoma and Lung cancer presented at the 107th Annual Meeting of American Association for Cancer Research (AACR-2016) (3182732; 3182741)
  • 26 Feb 2016 Bayer terminates a phase I trial in Lymphoma and Solid tumours (Late-stage disease) in United States, United Kingdom, France, Finland, Germany and Switzerland (NCT02369029)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top